Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.


Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
05 2019
Historique:
received: 19 04 2017
revised: 12 02 2018
accepted: 15 02 2018
pubmed: 24 4 2018
medline: 19 3 2020
entrez: 23 4 2018
Statut: ppublish

Résumé

This cross-sectional study aimed to describe the functional and structural cardiac abnormalities that occur across a spectrum of cardiac amyloidosis burden and to identify the strongest cardiac functional and structural prognostic predictors in amyloidosis using cardiac magnetic resonance (CMR) and echocardiography. Cardiac involvement in light chain and transthyretin amyloidosis is the main driver of prognosis and influences treatment strategies. Numerous measures of cardiac structure and function are assessed by multiple imaging modalities in amyloidosis. A total f 322 subjects (311 systemic amyloidosis and 11 transthyretin gene mutation carriers) underwent comprehensive CMR and transthoracic echocardiography. The probabilities of 11 commonly measured structural and functional cardiac parameters being abnormal with increasing cardiac amyloidosis burden were evaluated. Cardiac amyloidosis burden was quantified using CMR-derived extracellular volume. The prognostic capacities of these parameters to predict death in amyloidosis were assessed using Cox proportional hazards models. Left ventricular mass and mitral annular plane systolic excursion by CMR along with strain and E/e' by echocardiography have high probabilities of being abnormal at low cardiac amyloid burden. Reductions in biventricular ejection fractions and elevations in biatrial areas occur at high burdens of infiltration. The probabilities of indexed stroke volume, myocardial contraction fraction, and tricuspid annular plane systolic excursion (TAPSE) being abnormal occur more gradually with increasing extracellular volume. Ninety patients (28%) died during a median follow-up of 22 months (interquartile range: 10 to 38 months). Univariable analysis showed that all imaging markers studied significantly predicted outcome. Multivariable analysis showed that TAPSE (hazard ratio: 1.46; 95% confidence interval: 1.16 to 1.85; p < 0.01) and indexed stroke volume (hazard ratio: 1.24; 95% confidence interval: 1.04 to 1.48; p < 0.05) by CMR were the only independent predictors of mortality. Specific functional and structural abnormalities characterize different burdens of cardiac amyloid deposition. In a multimodality imaging assessment of a large cohort of amyloidosis patients, CMR-derived TAPSE and indexed stroke volume are the strongest prognostic cardiac functional markers.

Sections du résumé

OBJECTIVES
This cross-sectional study aimed to describe the functional and structural cardiac abnormalities that occur across a spectrum of cardiac amyloidosis burden and to identify the strongest cardiac functional and structural prognostic predictors in amyloidosis using cardiac magnetic resonance (CMR) and echocardiography.
BACKGROUND
Cardiac involvement in light chain and transthyretin amyloidosis is the main driver of prognosis and influences treatment strategies. Numerous measures of cardiac structure and function are assessed by multiple imaging modalities in amyloidosis.
METHODS
A total f 322 subjects (311 systemic amyloidosis and 11 transthyretin gene mutation carriers) underwent comprehensive CMR and transthoracic echocardiography. The probabilities of 11 commonly measured structural and functional cardiac parameters being abnormal with increasing cardiac amyloidosis burden were evaluated. Cardiac amyloidosis burden was quantified using CMR-derived extracellular volume. The prognostic capacities of these parameters to predict death in amyloidosis were assessed using Cox proportional hazards models.
RESULTS
Left ventricular mass and mitral annular plane systolic excursion by CMR along with strain and E/e' by echocardiography have high probabilities of being abnormal at low cardiac amyloid burden. Reductions in biventricular ejection fractions and elevations in biatrial areas occur at high burdens of infiltration. The probabilities of indexed stroke volume, myocardial contraction fraction, and tricuspid annular plane systolic excursion (TAPSE) being abnormal occur more gradually with increasing extracellular volume. Ninety patients (28%) died during a median follow-up of 22 months (interquartile range: 10 to 38 months). Univariable analysis showed that all imaging markers studied significantly predicted outcome. Multivariable analysis showed that TAPSE (hazard ratio: 1.46; 95% confidence interval: 1.16 to 1.85; p < 0.01) and indexed stroke volume (hazard ratio: 1.24; 95% confidence interval: 1.04 to 1.48; p < 0.05) by CMR were the only independent predictors of mortality.
CONCLUSIONS
Specific functional and structural abnormalities characterize different burdens of cardiac amyloid deposition. In a multimodality imaging assessment of a large cohort of amyloidosis patients, CMR-derived TAPSE and indexed stroke volume are the strongest prognostic cardiac functional markers.

Identifiants

pubmed: 29680336
pii: S1936-878X(18)30213-4
doi: 10.1016/j.jcmg.2018.02.016
pii:
doi:

Substances chimiques

Amyloid 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

823-833

Subventions

Organisme : British Heart Foundation
ID : FS/18/21/33447
Pays : United Kingdom
Organisme : British Heart Foundation
ID : NH/18/1/33511
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Daniel S Knight (DS)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.

Giulia Zumbo (G)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.

William Barcella (W)

Department of Statistical Science, University College London, United Kingdom.

Jennifer A Steeden (JA)

Centre for Cardiovascular Imaging, Institute of Cardiovascular Science, University College London and Great Ormond Street Hospital for Children, London, United Kingdom.

Vivek Muthurangu (V)

Centre for Cardiovascular Imaging, Institute of Cardiovascular Science, University College London and Great Ormond Street Hospital for Children, London, United Kingdom.

Ana Martinez-Naharro (A)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.

Thomas A Treibel (TA)

Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom.

Amna Abdel-Gadir (A)

Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom.

Heerajnarain Bulluck (H)

The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, United Kingdom.

Tushar Kotecha (T)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.

Rohin Francis (R)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.

Tamer Rezk (T)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.

Candida C Quarta (CC)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.

Carol J Whelan (CJ)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.

Helen J Lachmann (HJ)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.

Ashutosh D Wechalekar (AD)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.

Julian D Gillmore (JD)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.

James C Moon (JC)

Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom.

Philip N Hawkins (PN)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.

Marianna Fontana (M)

National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom. Electronic address: m.fontana@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH